kilawattmusic.com • Professional Insights • Expert Commentary • Resource Center
kilawattmusic.com

liraglutide approval in india Luxury Guide,Biocon Pharma Limited, has received approval for the Liraglutide drug product

Liraglutide Approval in India: A New Era for Diabetes and Weight Management 3 Jun 2025—Biocon Pharma Limited has received approval for its Liraglutide drug product(6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs 

liraglutide approval in india

liraglutide approval in india:BioconLiraglutide India

A
Nicholas Wood

studies 'liraglutide approval in india' engagement metrics and growth patterns with organized and accessible information on TikTok and Facebook

Published on

Executive Summary

liraglutide approval in india liraglutide 3 Jun 2025—Biocon Pharma Limited has received approval for its Liraglutide drug product(6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs 

The landscape of diabetes and weight management treatment in India has been significantly enhanced with the recent approval of liraglutide. This groundbreaking GLP-1 receptor agonist offers a new avenue for patients seeking effective control over their conditions. The approval process, overseen by regulatory bodies like the Central Drugs Standard Control Organisation (CDSCO), signifies a major step forward for both the pharmaceutical industry and public health in India.

Leading the charge in this development is Biocon Limited, a prominent global biopharmaceutical company. Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has been at the forefront, securing approval for its liraglutide drug product. This includes formulations such as the 6 mg/ml solution for injection in pre-filled pen and cartridge. This signifies Biocon Pharma Limited has received approval for its Liraglutide drug product. The approval is not just for a single indication; Biocon receives CDSCO approval for liraglutide, enhancing diabetes treatment options for Indian patients with a cost-effective GLP-1 solution.

The approval for liraglutide in India is multifaceted. It is indicated for the treatment of Type 2 diabetes in individuals aged 10 and above, offering a new therapeutic option for a significant patient population. Furthermore, Biocon obtains approval for weight management drug, liraglutide, highlighting its dual utility. This approval for the generic version of Victoza, a widely prescribed treatment, marks a milestone in chronic weight management and insufficient control of Type 2 Diabetes.

The journey to this approval has involved rigorous clinical trials and regulatory scrutiny. Research has demonstrated the efficacy of liraglutide in the Indian population. For instance, studies have shown Liraglutide therapy demonstrated HbA1c reduction in the Indian population up to 2.26% and 2.54%, over 24 and 52 weeks, respectively. Furthermore, the efficacy and safety of liraglutide in Indian adolescents with obesity have also been evaluated, with studies indicating positive outcomes. These findings contribute to a robust body of evidence supporting the use of liraglutide in India.

Beyond Biocon Limited, other pharmaceutical players are also making strides in the liraglutide market in India. Glenmark Pharma has been a notable contributor, being the first to launch a biosimilar of this popular anti-diabetic drug. This biosimilar, marketed under the brand name Lirafit, received approval from the Drug Controller General of India (DCGI) in January 2024. The launch of Lirafit India by Glenmark signifies increased accessibility and affordability of this crucial medication.

The regulatory framework in India plays a vital role in ensuring the safety and efficacy of new drugs. The Central Drugs Standard Control Organisation (CDSCO) is the primary authority responsible for granting such approvals. The approval process involves thorough review of data, and any approval granted by the Ethics Committee must be communicated to the Central Licensing Authority within fifteen working days. This diligent oversight ensures that only high-quality medications reach the Indian market.

The significance of liraglutide approval in India extends beyond just the availability of a new drug. It represents a broader trend towards increased access to advanced therapies for chronic diseases. Biocon shares rise on CDSCO approval in India for Liraglutide, underscoring the economic and market impact of this development. This expansion of affordable diabetes care, with Biocon's first integrated GLP-1 treatment, is a testament to the company's commitment to improving healthcare outcomes.

International regulatory bodies have also recognized the potential of liraglutide. Biocon Limited on Tuesday received USFDA approval for its generic version of Liraglutide Injection (18 mg/3 mL), a GLP-1 weight management drug. Similarly, Biocon Ltd received USFDA approval for Liraglutide Injection gSaxenda, further validating the drug's efficacy and safety profile on a global scale. Lupin receives USFDA approvals for Liraglutide and Glucagon injectable products also highlight the global reach and acceptance of this therapeutic class. These international approvals often pave the way for enhanced domestic access and further research.

While the focus has been on diabetes and weight management, the versatility of liraglutide is becoming increasingly apparent. The approval signifies a new chapter in the management of these conditions in India, offering hope and improved health outcomes for countless individuals. The availability of liraglutide in various forms, including injections, ensures tailored treatment approaches. The liraglutide drug substance and its finished product forms are now accessible, marking a significant advancement. The approval for liraglutide in India is a crucial step towards a healthier future for the Indian population.

Related Articles

Frequently Asked Questions

Here are the most common questions about liraglutide approval in india.

Biocon Secures Approval for Liraglutide Diabetes Treatment
Efficacy and safety of liraglutide in Indian adolescents with
Biocon (+ve) Gets approval for diabetes drug Liraglutide in IndiaGLENMARK PHARMA (+ve) Receives positive results for trials on anti-body 
3 Jun 2025—Biocon Limited, a global biopharmaceutical company, has announced that the company has received approval in India for its Liraglutide drug substance.

Leave a Comment

Share your thoughts, feedback, or additional insights on this topic.

Explore More